Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
25 July 2013Website:
http://www.histogen.comNext earnings report:
03 July 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | Fri, 28 Jun 2024 13:30:00 GMTDividend
Analysts recommendations
Institutional Ownership
What type of business is Histogen?
Histogen Inc., a clinical-stage therapeutics company, focuses on developing proprietary hypoxia-generated growth factor technology platform and stem cell-free biologic products. It offers HST-003, a human extracellular matrix, which is in Phase 1/2 clinical trial to treat articular cartilage defects in the knee; HST-004, a cell conditioned media solution to treat spinal disc repair; and Emricasan, an orally active pan-caspase inhibitor for the treatment of COVID-19. The company's preclinical product candidates include CTS-2090 and CTS-2096, which are selective caspase-1 inhibitors targeting inflammasome activation, as well as intervenes in a various inflammation mediated disease. Histogen Inc. was founded in 2007 and is headquartered in San Diego, California.
What sector is Histogen in?
Histogen is in the Healthcare sector
What industry is Histogen in?
Histogen is in the Biotechnology industry
What country is Histogen from?
Histogen is headquartered in United States
When did Histogen go public?
Histogen initial public offering (IPO) was on 25 July 2013
What is Histogen website?
https://www.histogen.com
Is Histogen in the S&P 500?
No, Histogen is not included in the S&P 500 index
Is Histogen in the NASDAQ 100?
No, Histogen is not included in the NASDAQ 100 index
Is Histogen in the Dow Jones?
No, Histogen is not included in the Dow Jones index
When does Histogen report earnings?
The next expected earnings date for Histogen is 03 July 2024